Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Jenna who wrote (23232)	1/28/1999 10:48:00 AM
From: RCJIII	Respond to of 120523

CHS Conference call, very positive, earnings of .40 to .45 expected for this year ending this June, creates PE or 5 to 6. Some other highlights- Core Career Line sales up 18%, Revamping Casual Line to emulate Core Line's strength Soon to announce entirely new Division and Line, retailers have expressed excitement about it. It will open this February. They have hired an advertising firm to strengthen brand recognition. They have substantially grown sales with NO advertising. This new campaign could really help expand sales, brand recognition and stock price as the company gains greater exposure. Their goal is to expand into another 200 to 300 stores this year. Website to open within 30 days, they are considering on-line sales but it is still just at the consideration stage. Everything looks very positive going forward. This is a terrific short and long term holding. RCJIII

To: Jenna who wrote (23232)	1/28/1999 11:50:00 AM
From: j g cordes	Respond to of 120523

HIV.. at 2 1/2 > 9/16. Herpes simplex is one of the world's most sought after cures. If this is a gain over Zovirax and some other anti-virals then this is significant. Article : "Herpes Vaccine Effective in Animals VIENNA, Va., Jan. 28 /PRNewswire/ -- In a study published in the latest issue of Vaccine, researchers at CEL-SCI CORPORATION (Amex: HIV, Berlin Stock Exchange: LSR) and Dr. Kenneth S. Rosenthal of Northeastern Ohio Universities College of Medicine (NEOUCOM), Rootstown, Ohio, demonstrated increased survival in mice after challenge with the herpes simplex virus. The immunizations allowed the animals to fight the infection much more quickly and effectively, resulting in reduced symptoms and mortality. Dr. Rosenthal said, ''It is significant to note that this protection appears to be due solely to cellular (e.g., T-Cell) immune response. We were not able to find antibodies to the vaccines in the animals.'' These new vaccines are based upon CEL-SCI's patented L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) technology. They consist of two protein pieces (peptides). The first is a copy of a small portion of a herpes simplex virus protein and the second is a T-cell binding ligand. The combination of these two peptides is a herpes simplex L.E.A.P.S. vaccine. The T-cell binding ligand increases the effectiveness of the vaccine by directing the immune response in a way most likely to eliminate or control the disease, which, in the case of herpes simplex, is thought to be the cellular immune response. The viral protein (in the form of a peptide) given without the T- cell binding ligand accelerated disease progression and mortality, while the addition of the T-cell binding ligand made the viral protein protective. Thursday January 28, 8:31 am Eastern Time Company Press Release SOURCE: CEL-SCI Corporation"